Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
- Status
- RECRUITING
- Phase
- PHASE2
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
- Status
- RECRUITING
- Phase
- PHASE2
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2